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Abstract
One of the characteristics of obesity-associated diabetes is an elevated fasting plasma insulin concentration with a weak
insulin secretory response to subsequent glucose stimulation. Evidence suggests that hyperglycemia and hyperlipidemia may
contribute to the initiation and progression of this disordered islet glucose sensing. It has been proposed that reducing
hyperglycemia and hyperlipidemia per se may improve islet glucose sensing. Here we studied glucose-dependent insulin
release in islets isolated from ob/ob mice treated with dopamine agonists (bromocriptine and SKF38393, BC/SKF) which
significantly reduced circulating glucose and lipid levels of ob/ob mice. Islets from BC/SKF-treated mice showed a marked
decrease of the elevated basal insulin release to levels similar to lean mice. Such treatment also induced a higher secretory
response to glucose stimulation compared with that in ob/ob mice with sustained hyperglycemia and hyperlipidemia.
Similarly, when islets from untreated ob/ob mice were cultured for 7 days in 11 mM glucose in the absence of free fatty acid,
the basal insulin release was significantly decreased and high glucose stimulated insulin release increased compared with that
from islets cultured in medium containing 30 mM glucose and 2 mM oleate. The BC/SKF-induced reduction of elevated
basal insulin release was associated with decreased hexokinase activity and basal cyclic AMP content in islet tissue. Our
results demonstrate that dopamine agonist treatment improves basal insulin release in ob/ob mice and this effect may be
mediated, in part, by a reduction of hyperglycemia and hyperlipidemia. ß 1998 Published by Elsevier Science B.V. All
rights reserved.
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1. Introduction
Pancreatic islet desensitization to glucose is a com-
mon characteristic of obesity-associated diabetes.
This glucose blindness leads to a high insulin level in
the fasted state, but a weak postprandial secretory
response. Mechanisms responsible for this disorder
in glucose regulated insulin release are unclear. How-
ever, elevated circulating glucose and free fatty acid
(FFA) levels have strong in£uences on islet glucose
sensing [1^6]. In humans, chronic hyperglycemia in-
duced by glucose infusion diminishes the subsequent
increase of insulin release following a rise in plasma
glucose level [1]. The same defect was also observed
in experimental animals [2,3]. Moreover, reducing
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the blood glucose by administration of insulin is
able to markedly improve glucose-induced insulin
release in diabetic patients [4] and in animals [7].
Chronic increases in extracellular FFA level, either
in vivo or in vitro, markedly increase islet basal in-
sulin release at low glucose concentrations, but
signi¢cantly inhibit high glucose-stimulated insulin
secretion from pancreatic L-cells [8^10]. These obser-
vations lead to the working hypothesis that hyper-
glycemia and/or hyperlipidemia may have toxic ef-
fects on islets and thus play an important role in
the initiation and progression of the islet dysfunction
of type II diabetes [11^13]. A correlate of this hy-
pothesis is that amelioration of hyperglycemia and
hyperlipidemia, per se, should be able to improve
islet glucose sensing in the obese-associated diabetic
condition.
The ob/ob mouse exhibits an elevated basal insulin
release associated with enhanced blood glucose and
FFA levels [14^16]. We have recently demonstrated
that co-administration of the dopamine D2 and D1
agonists, bromocriptine and SKF38393 (BC/SKF),
respectively, synergistically attenuated the severe
obesity, hyperglycemia and hyperlipidemia of obese
(ob/ob) mice [17]. We therefore examined the possi-
bility that a combination of BC and SKF treatment
may also improve dysfunction of the islet glucose
sensing in these mice. We found that 2 weeks treat-
ment of ob/ob mice with BC/SKF reduced hypergly-
cemia, hyperlipidemia, and the elevated basal insulin
release from islets compared with that in control ob/
ob mice. Moreover, glucose-stimulated insulin release
in treated mice was enhanced compared with that in
controls. A similar islet response to chronic in vitro
changes in extracellular glucose and lipid concentra-
tions was observed in islets of untreated ob/ob mice,
suggesting a reduction of glucose and lipid levels
plays an important role in the improvement of islet
glucose sensing. A decrease of hexokinase activity
and cAMP content in islets from BC/SKF-treated
ob/ob mice was observed and may, in part, mediate
the reduced basal insulin release in isolated islets
from these mice. Our results suggest that eliminat-
ing the hyperglycemia and hyperlipidemia of the
ob/ob mice may be a mediating factor in BC/SKF
induced improvement of disordered glucose-regu-
lated insulin release typical of the obese diabetic
condition.
2. Materials and methods
2.1. Experimental design
Six-week-old C57BL/6J ob/ob mice and their lean
littermates (C57BL/6J +/+) were housed two per cage
on a 12:12-h light/dark cycle environment and fed
rodent chow (PMI Feeds, St. Louis, MO) ad libitum.
The ob/ob mice were divided into two groups and
treated for 2 weeks with BC (13 mg/kg)/SKF (10
mg/kg) or vehicle i.p. at 1 h after light onset.
Twenty-four hours after the last injection, mice
were killed to collect blood samples and pancreatic
tissue. Rodents, including mice, exhibit very marked
and reproducible circadian variations in feeding with
food consumption, being predominately restricted to
an approximate 8-h interval during the dark (noctur-
nal) period of the day. In this study, all plasma sam-
ples were collected at 1 h after light onset, which is
approximately 3 h post-feeding. A forced overnight
fast was not employed in these studies. This exper-
imental design allows for metabolite analysis under
controlled (reproducible) and natural conditions. The
aim was to assess the e¡ects of neuroendocrine ma-
nipulation with dopamine agonists on the natural
course of metabolism. In addition, in previous ex-
periments we measured blood glucose and FFA
over a 24-h period. In BC/SKF-treated ob/ob mice,
these two parameters were markedly reduced at all
the time points of the day we measured [18]. Pancre-
atic islets were isolated by collagenase digestion and
picked up by pipette after Ficoll gradient centrifuga-
tion. These islets were then utilized for insulin release
studies and biochemical analyses.
Another group of ob/ob mice was used for islet
organ culture and did not receive any treatment be-
fore islet isolation. Islets from these ob/ob mice were
cultured for 7 days in RPMI 1640 (pH 7.4) with
di¡erent glucose and oleate concentrations as de-
scribed in Section 3. Then, these cultured islets
were used to study glucose-induced insulin release
by static incubation as described below.
2.2. Determination of metabolites and hormones in the
blood
Blood glucose was measured by glucose monitor
(Accu-Check Advantage, Boehringer, Indianapolis,
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IN). Plasma FFA was determined by enzymatic as-
say utilizing acyl-CoA synthetase and acyl-CoA oxi-
dase coupled to peroxidase (Wako Chemicals, Rich-
mond, VA). Triglyceride concentration in the plasma
was determined enzymatically utilizing lipoprotein
lipase coupled to glycerol kinase (Sigma Diagnostics,
St. Louis, MO). Commercially available radioimmu-
noassay (RIA) kits were utilized to measure the plas-
ma concentrations of insulin and glucagon (Linco
Research, St. Charles, MO).
2.3. Glucose-induced insulin release studies using
isolated islets
Insulin release induced by various glucose concen-
trations was studied using islet static incubation de-
scribed previously [19]. A group of 10 islets was
loaded in each incubation tube. After 20 min pre-
incubation, islets were transferred to incubation bu¡-
er (Hepes-bu¡ered Krebs^Ringer bu¡er (pH 7.4),
Hepes^KRB) containing di¡erent glucose concentra-
tions. Both the pre-incubation and incubation were
performed at 37‡C in a water bath shaker with an
atmosphere of 95% O2/5% CO2. Basal insulin release
was tested at 2.5 and 5 mM glucose, and glucose-
stimulated insulin release was examined using
8^20 mM glucose. Samples of incubation bu¡er
were collected at 0 and 60 min for insulin determi-
nation (Linco Research, St. Charles, MO).
The bi-phasic response of insulin release stimu-
lated by 15 mM glucose was tested by islet perfusion
[20]. Fifty islets were loaded in the perfusion cham-
ber and perfused with Hepes^KRB containing 5 mM
glucose. After 40 min, islets were exposed to 15 mM
glucose for 30 min. Fractions of perfusate were col-
lected at 1- or 5-min intervals for insulin RIA.
The DNA content in isolated islets was determined
by a £uorometric method using a DyNA Quant 200
Fluorometer (Hoefer Pharmacia Biotech, San Fran-
cisco, CA). Insulin content in isolated islets was
measured by RIA following extraction by acid^etha-
nol.
2.4. Hexokinase and glucokinase activity
determination
A radiometric macroassay was used to determine
the hexokinase and glucokinase activities in the
total islet tissue [21]. 3H2O liberated from D-[2-
3H(N)]glucose 6-phosphate by phosphoglucose iso-
merase was allowed to di¡use from the D-[2-
3H(N)]glucose by incubation overnight at 30‡C.
3H2O (DuPont-NEN, Billerica, MA) standard was
used to calculate the di¡usion e⁄ciency. The hexoki-
nase activity was measured at 0.03, 0.06, 0.13, 0.25
and 0.5 mM glucose concentrations. The Vmax and
Km of hexokinase were analyzed by Hanes^Woolf
plots. Glucokinase was determined only at the
15 mM glucose concentration due to sample avail-
ability limitations. Glucose phosphorylation activity
at 0.5 mM glucose (representing hexokinase maximal
activity) was subtracted in the calculation of gluco-
kinase activity at 15 mM glucose.
2.5. Cyclic AMP assay
Groups of 20 islets were pre-incubated with
Hepes^KRB in the absence of glucose for 20 min
at 37‡C in a metabolic shaker gassed by 95% O2/
5% CO2. After being exposed to 5 or 15 mM glucose
for 15 min, these islets were immediately frozen on
dry ice and stored at 380‡C. For cAMP extraction,
islets were sonicated in 1 ml 6% trichloroacetic acid
and the supernatant was washed with 5 volumes of
water saturated diethyl ether. The aqueous extract
remaining was then dried and re-dissolved in the as-
say bu¡er. A radioimmunoassay (Amersham Life
Science) was applied to measure the cAMP content
in these samples.
2.6. Protein kinase C (PKC) immunoblotting
Pancreatic islets were isolated from lean controls
and ob/ob mice receiving vehicle or BC/SKF treat-
ment, and immediately frozen. Islet samples were
sonicated in Tris bu¡er (20 mM Tris (pH 7.4)/0.5
mM EGTA/50 WM leupeptin/1 mM PMSF/0.1%
2-mercaptoethanol/10 WM pepstatin A). The islet
particulate fraction was separated from cytosol by
a 60-min ultracentrifugation at 250 000Ug at 4‡C.
The islet samples were then mixed 1:1 with the sam-
ple bu¡er (62.5 mM Tris (pH 6.8)/2% sodium dodec-
yl sulfate/10% glycerol/5% 2-mercaptoethanol/
0.002% bromophenol blue). Approximately 20 Wg
of protein from each sample was loaded on the
SDS^polyacrylamide gel prepared with a 10% acryl-
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amide concentration. After electrophoresis, protein
components were transferred to a nitrocellulose ¢lter
by semi-dry blotting and blocked by 2% BSA/0.5%
Tween-20 in 100 mM Tris bu¡er (pH 7.4) at room
temperature for 60 min. The ¢lter was than incu-
bated overnight at 4‡C with rabbit anti-PKC-K anti-
serum (Gibco BRL, Gaithersburg, MD) at 1:5000
dilution. Detection of the bound antibody was per-
formed using horseradish peroxidase-conjugated
anti-rabbit IgG (Pierce, Rockford, IL) at 1:2000 di-
lution followed by enhanced chemical luminescence
detection (Amersham, Buckinghamshire, UK). The
same ¢lter was stripped and reused for PKC-O and
actin detection using rabbit anti-PKC-O antiserum
(1:5000, Gibco) or rabbit anti-actin antiserum
(1:2000, Sigma).
2.7. Data expression
The data of insulin release, hexokinase activity and
cAMP content were calculated and expressed per
DNA content in islet to normalize for the size di¡er-
ence of pancreatic islets (e.g., cellular content) be-
tween the ob/ob mice and their lean littermates. A
two-way analysis of variance (ANOVA) was applied
in all data analyses. Intensity of the immunoreaction
bands was quantitated by computerized image
analysis using Molecular Analyst (Bio-Rad,
Hercules, CA). The intensity of actin bands was
used as a reference in the calculation of the
intensity of PKC-K or PKC-O bands in the same
sample.
Table 1
E¡ect of BC/SKF treatment on metabolites and hormones in ob/ob mice
Body weight
(g)
Blood glucose
(mM)
Plasma FFA
(mM)
Plasma TG
(mg/dl)
Plasma insulin
(pmol/ml)
Plasma glucagon
(pg/ml)
Lean mice 20.9 þ 0.3 7.5 þ 0.2 0.66 þ 0.07 160 þ 7.5 0.2 þ 0.03 67.8 þ 7.5
ob/ob Control 43.0 þ 0.7** 17.0 þ 1.0** 0.94 þ 0.08* 285 þ 32** 8.5 þ 0.8** 231.3 þ 27.4**
ob/ob BC/SKF 36.8 þ 0.5**;33 10.1 þ 0.4;33 0.73 þ 0.0533 160 þ 1033 4.6 þ 0.6*;33 84.6 þ 6.733
*P6 0.05, **P6 0.01 compared with that in lean mice.
3P6 0.05, 33P6 0.01, compared with that in ob/ob control.
Fig. 1. Glucose-induced insulin release from islets of lean and ob/ob mice treated with BC/SKF or vehicle treatment. (A) Insulin re-
lease from isolated islets incubated in media containing di¡erent glucose concentrations. (B) Insulin release from isolated islets peri-
fused with bu¡er containing 5 or 15 mM glucose concentration. (b) Lean mice; (a) ob/ob controls; (S) BC/SKF treated ob/ob mice.
*P6 0.05 and **P6 0.01, compared with lean mice. pP6 0.05 and ppP6 0.01, compared with ob/ob controls (two-way ANOVA,
n = 6).
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3. Results
3.1. E¡ect of BC/SKF treatment on metabolites and
hormones
At 1 h after light onset, blood glucose, and plasma
FFA, triglyceride, insulin, and glucagon levels in ob/
ob mice are all signi¢cantly higher than that in their
lean littermates. A 2-week treatment of ob/ob mice
with BC/SKF reduced the blood glucose level (by
40%), the plasma FFA and triglyceride concentra-
tions were signi¢cantly deceased (by 24% and 44%,
respectively) to a level similar to that of their lean
littermates. Similarly, such treatment also reduced
the plasma insulin level (50%) and the plasma gluca-
gon level was decreased (63%) to a level similar as
that in lean mice (Table 1).
3.2. Glucose-induced insulin release from isolated
islets of ob/ob mice and their lean littermates
To study the glucose dose-dependency of insulin
release, islets isolated from ob/ob mice (treated by
BC/SKF or vehicle) and their littermates were incu-
bated in the Hepes^KRB containing di¡erent glucose
concentrations ranging from 2.5 to 20 mM for
60 min. Insulin secretion data is shown in Fig. 1A.
Islets from lean mice showed little insulin release
when they were incubated in 2.5 or 5 mM glucose,
but a 4-fold increase of insulin secretion when the
glucose concentrations were increased to 15^20 mM.
In ob/ob controls, insulin release from islets incu-
bated in 2.5 or 5 mM glucose was markedly in-
creased (172% and 262%) compared with that in
lean mice (P = 0.051 and P6 0.01, respectively).
When the glucose concentration in the incubation
bu¡er was increased, islets from ob/ob mice showed
an approximate 3-fold enhancement of insulin re-
lease. These observations are consistent with pre-
vious studies of ob/ob mice [14,15]. In ob/ob mice
treated with BC/SKF which signi¢cantly reduced
blood glucose and lipid levels, the insulin release
from islets incubated at 2.5 or 5 mM glucose was
reduced by at least 40% compared with that in ob/
ob controls and to levels observed in lean mice when
insulin release was expressed per DNA or per insulin
content in islet (Table 2). Contrariwise, when the
glucose concentration in the incubation bu¡er was
increased, islets from treated ob/ob mice secreted
much more insulin than that in ob/ob controls
when normalized to DNA content. When we calcu-
lated the insulin release as the fraction of the islet
Table 2
Insulin release as per DNA unit or as the fraction of islet insulin content in freshly isolated or cultured islets from ob/ob mice and
their lean littermates
Islet DNA
content
(ng/islet)
Insulin release
(fmol/ng DNA/h)
Insulin content
(fmol/ng DNA)
Insulin release
(% of islet insulin content/h)
-Fold increase
(5 vs. 15 mM
glucose)
5 mM G 15 mM G 5 mM G 15 mM G
Fresh islets
Lean mice 16.0 þ 0.8 3.0 þ 0.5 11.1 þ 1.5 285.4 þ 42.7 1.0 þ 0.2 3.9 þ 0.5 3.8
ob/ob Control 31.3 þ 2.2** 7.8 þ 1.2** 20.0 þ 2.2 187.7 þ 53.2 4.1 þ 0.6** 10.6 þ 1.2** 2.6
ob/ob BC/SKF 24.0 þ 2.0**;33 4.6 þ 0.7*;3 31.8 þ 5.2*;3 470.9 þ 73.4;33 0.9 þ 0.133 6.8 þ 1.13 7.3
Islets cultured for 7 days in:
30 mM G/2 mM
OA
17.2 þ 1.64 4.3 þ 1.24 3.4 þ 0.6 45.7 þ 12.34 9.3 þ 2.64 7.4 þ 1.24 0.8
30 mM G 19.4 þ 2.0 2.8 þ 1.5 6.5 þ 1.64 85.3 þ 3.84 3.3 þ 1.8 7.6 þ 1.84 2.3
11 mM G/2 mM
OA
16.5 þ 2.4 1.6 þ 0.7 2.1 þ 0.5 60.3 þ 9.34 2.6 þ 1.1 3.5 þ 0.8 1.4
11 mM G 18.7 þ 2.1 0.8 þ 0.1 3.4 þ 0.8 185.7 þ 16.8 0.4 þ 0.0 1.8 þ 0.5 4.4
*P6 0.05, **P6 0.01 compared with that in lean mice.
3P6 0.05, 33P6 0.01, compared with that in ob/ob control.
4P6 0.01 compared with islets cultured in 11 mM glucose.
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insulin content, insulin release per insulin content
was reduced by BC/SKF treatment in response to
high glucose concentrations as shown in Table 2.
The bi-phasic response of insulin release from ob/
ob mice and their lean littermates was examined by
islet perfusion. Islets from lean, ob/ob control or
treated ob/ob mice all showed a bi-phasic response
of insulin release and the BC/SKF-treated mice ex-
hibited the highest insulin secretion response to
15 mM glucose compared with that in lean and ob/
ob controls (Fig. 1B).
3.3. Glucose-induced insulin release from cultured
islets isolated from untreated ob/ob mice
We utilized an islet organ culture method to test
whether improved insulin release in ob/ob mice
treated with BC/SKF may be due to a reduction of
blood glucose and lipid levels in these mice. Islets
were isolated from untreated ob/ob mice and cultured
for 7 days in RPMI 1640 medium under one of four
di¡erent culture conditions: (1) 30 mM glucose with
2 mM oleate; (2) 30 mM glucose; (3) 11 mM glucose
with 2 mM oleate; and (4) 11 mM glucose. After
7 days of culture, glucose-induced insulin release
was tested by static incubation (Fig. 2). Islets cul-
tured in 30 mM glucose and 2 mM oleate showed
the highest basal insulin release (2.9 þ 0.5 fmol/ng
DNA per h in response to 2.5 mM glucose) com-
pared with that in islets cultured in 11 mM glucose
(0.6 þ 0.2 fmol/ng DNA per h, P6 0.01) similar to
the di¡erences between hyperglycemic, hyperlipidem-
ic ob/ob mice and BC/SKF-treated mice, respectively.
Islets cultured in 30 mM glucose alone (1.94 þ
0.50 fmol/ng DNA per h) still exhibited a higher
release than islets cultured in 11 mM glucose
(P6 0.05, Fig. 2A). When cultured islets were stimu-
lated with 8 or 15 mM glucose, the insulin release
Fig. 2. Comparison of basal and glucose-stimulated insulin release in freshly isolated or cultured islets. (A) Insulin release from islets
incubated in media containing 2.5 mM glucose. (B) Glucose-stimulated insulin release from freshly isolated islets of ob/ob control and
BC/SKF-treated mice. Data are expressed as the percentage of basal insulin release at 2.5 mM glucose. (C) Glucose-stimulated insulin
release from islets cultured for 7 days in RPMI 1640 containing di¡erent glucose and oleate concentrations. Data are expressed as the
percentage of basal release at 2.5 mM glucose in the incubation media.
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from islets cultured in 30 mM glucose plus 2 mM
oleate showed the least stimulatory increase above
basal compared to all other groups (P6 0.05). The
best glucose-stimulated insulin response was ob-
served in those islets cultured with 11 mM glucose
(P6 0.01 compared with islets cultured in 30 mM
glucose with 2 mM oleate) which showed a 5-fold
increase of insulin release stimulated by 15 mM glu-
cose, the magnitude of which was comparable with
that in freshly isolated islets from BC/SKF-treated
mice (Fig. 2B,C). We also cultured islets from lean
mice using the same conditions and test insulin re-
lease at di¡erent glucose concentrations. As observed
similarly in islets from ob/ob mice, 30 mM glucose
plus 2 mM oleate markedly increased basal insulin
release and reduced glucose-stimulated insulin secre-
tion (data not shown).
3.4. Hexokinase and glucokinase activity in pancreatic
islets
To investigate the possible cellular mechanism(s)
by which BC/SKF reduced basal insulin release in
ob/ob mice, the activities of hexokinase and glucoki-
nase in islet tissue were determined (Table 3). The
Vmax of hexokinase in islets of ob/ob mice was
2-fold higher than that in lean mice. BC/SKF treat-
ment markedly reduced the activity of hexokinase in
islet tissue to the value observed in lean mice. The
values of glucose Km of hexokinase in lean or ob/ob
mice were the same. Islet glucokinase activity was
measured at 15 mM glucose. Both ob/ob control
and treated mice showed a signi¢cantly increased ac-
tivity of glucokinase compared with that in lean
mice. The ratio of glucokinase (at 15 mM glucose)
to maximal hexokinase activity in islet of lean, ob/ob
control and BC/SKF-treated mice were 2.75, 2.79
and 5.31, respectively.
3.5. Islet cAMP content and insulin release response
to forskolin
The cAMP content in islet tissue was measured by
radioimmunoassay (Fig. 3A). In ob/ob controls, the
basal cAMP content in islet tissue was signi¢cantly
increased compared with that in lean mice. BC/SKF
treatment reduced the islet basal cAMP content by
50% (P6 0.05 compared with that in ob/ob control).
As such, BC/SKF treatment resulted in a signi¢-
cantly deceased cAMP content among islets incu-
bated in 5 mM glucose compared with vehicle-
treated controls. However, exposing islets to 15 mM
glucose signi¢cantly increased the cAMP content in
islets from lean and BC/SKF-treated ob/ob mice,
whereas the cAMP content in islets from ob/ob con-
Fig. 3. E¡ect of BC/SKF on islet cAMP content and forskolin
stimulated insulin release from pancreatic islets of lean, control
and treated ob/ob mice. (A) The cAMP content in islets at basal
condition (absence of glucose), or after expose to 5 or 15 mM
glucose for 15 min. (B) Forskolin-stimulated insulin release
from islets incubated in media containing 5 or 15 mM glucose.
*P6 0.05 and **P6 0.01, compared with basal condition in
each group. #P6 0.05 and ##P6 0.01, compared with that in
lean mice under the same condition. pP6 0.05, compared with
that in ob/ob controls under the same condition.
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trols was similar in both the basal and high glucose
conditions.
The forskolin-stimulated insulin release was tested
at 5 and 15 mM glucose. When islets from lean mice
were incubated in bu¡er containing 5 mM glucose,
forskolin had no stimulatory e¡ect on insulin release.
However, in islets of ob/ob controls, forskolin in-
creased insulin release by 2- and 4-fold at 1 and
10 WM, respectively. In islets of BC/SKF-treated
ob/ob mice, only 10 WM forskolin signi¢cantly in-
creased insulin release (Fig. 3B). Therefore BC/SKF
treatment resulted in a reduced forskolin-stimulated
insulin release at 0.1 and 1 WM compared with ob/ob
controls (P6 0.01). When 15 mM glucose was added
in the media, the forskolin e¡ect on insulin release
was the same in islets from all three groups of mice
(Fig. 3B).
3.6. PKC content in islet tissue and TPA-stimulated
insulin release
The PKC-K and PKC-O contents in islet tissue
were detected by immunoblotting (Fig. 4). Actin con-
tent in the same ¢lter was used to normalize level of
PKC. PKC-K and PKC-O contents in the total islet
sample were similar among ob/ob controls and their
lean littermates. The cytosol content of PKC-K in ob/
ob mice was 6-fold higher than that in lean mice.
However, In the particulate fraction, the intensity
of the PKC-K band in islets of ob/ob mice was similar
to that in lean mice, while the band of PKC-O
showed approximately a 70% higher intensity com-
pared with that in lean mice. No marked di¡erence
in PKC-K or PKC-O was observed between islets ob-
tained from ob/ob control or treated mice.
Fig. 4. E¡ect of BC/SKF on PKC-K and PKC-O contents and TPA-stimulated insulin release from pancreatic islets of lean mice, con-
trol and treated ob/ob mice. (A) The PKC-K and PKC-O content in freshly isolated pancreatic islets. T, total islet tissue; C, cytosol
fraction; P, particulate fraction. (B) TPA-stimulated insulin release from islets incubated in media containing 5 or 15 mM glucose.
*P6 0.05 and **P6 0.01, compared with basal condition in each group.
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The insulin release induced by TPA was tested at
5 and 15 mM glucose concentrations. At 5 mM glu-
cose, TPA-stimulated insulin release in ob/ob mice
was much higher than that in lean mice, as has
been reported from other laboratories [22,23]. BC/
SKF treatment did not change the islet response to
TPA in ob/ob mice. When incubated in bu¡er with
15 mM glucose, the e¡ect of TPA on insulin release
was not di¡erent among islets from any of the three
groups of mice.
4. Discussion
The present study is the ¢rst to demonstrate that
BC/SKF treatment can reduce the elevated basal in-
sulin release of isolated islets from ob/ob mice to
levels observed in lean mice. Moreover, islet insulin
release stimulated by high glucose was signi¢cantly
higher in BC/SKF-treated mice than that in ob/ob
controls when expressed as either per nanogram islet
DNA or as a percentage of basal insulin release.
Even though dopaminergic agonists can inhibit glu-
cose-stimulated insulin release [24,25], we found a
combination of BC/SKF (1 WM of each) has no di-
rect e¡ect on insulin release from isolated islets in-
duced by 8 mM glucose [26]. Our previous study
showed that BC/SKF might a¡ect the neuroendo-
crine system to improve peripheral energy metabo-
lism and islet function, rather than having a direct
e¡ect on pancreatic islets [26]. In the present experi-
ments, islet studies were performed 24 h after the
¢nal BC/SKF treatment. Given BC/SKF has a very
short half-life, it is unlikely that these islet responses
could be attributed to a direct e¡ect of BC/SKF on
the pancreatic islet. Thus, the improved islet glucose
sensing in ob/ob mice treated by BC/SKF may be the
consequence of neuroendocrine regulation and/or a
result of the reduced hyperglycemia and hyperlipide-
mia. Here we examined the possible role of a reduc-
tion in circulation glucose and lipid in the improve-
ment of islet function using an islet culture method.
Our results show that reducing glucose and FFA
concentrations in the culture medium did improve
the glucose responsiveness of islets from ob/ob
mice. Islets cultured in low glucose/FFA media
showed reduced basal insulin release and higher glu-
cose-stimulated insulin secretion, which were similar
to those observed in freshly isolated islets from BC/
SKF-treated ob/ob mice (Fig. 1). Furthermore, our
preliminary data showed an approximate 70% de-
crease of triglyceride and fatty acids content in islets
from BC/SKF-treated mice compared with that in
controls. Elevated intracellular triglyceride stores
have been implicated in lipotoxicity to islets [27]
Therefore, it is very possible that reducing blood
glucose and lipid levels played a key role in the
BC/SKF e¡ect to improve islet function. It has
been reported that increased ambient glucose and
FFA levels, as well as an increased lipogenic capacity
in islet tissue could severely damage islet function
and induce cell apoptosis in obese and diabetic rats
[11,28,29]. Moreover, leptin or troglitazone markedly
lower the triglyceride content in islets and also re-
store islet function [30,31]. Our study in ob/ob mice
is consistent with these observations even though
BC/SKF may ameliorate hyperglycemia and hyper-
lipidemia via di¡erent mechanisms compared with
leptin or troglitazone [26]. BC/SKF treatment also
normalizes hyperphagia of ob/ob mice [17], while
the basal insulin release at 5 mM glucose using islets
isolated from pair fed ob/ob mice showed no marked
di¡erence compared with that in islets from ob/ob
controls (data not shown). The explanation may
Table 3
Hexokinase and glucokinase activity in pancreatic islets
Hexokinase Glucokinase activity (at 15 mM G)
(pmol/h/ng DNA)
Vmax (pmol/h/ng DNA) Km (mM)
Lean mice 2.96 þ 0.49 0.12 þ 0.01 8.14 þ 1.07
ob/ob Control 5.81 þ 0.75** 0.13 þ 0.01 16.24 þ 0.79**
ob/ob BC/SKF 3.50 þ 0.373 0.10 þ 0.02 18.58 þ 2.20**
**P6 0.01 compared with that in lean mice.
3P6 0.05 compared with that in ob/ob control.
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well be that food restriction of ob/ob mice does not
reduce the plasma FFA levels and only moderately
reduced blood glucose level [52]. Importantly, the
toxic e¡ects of elevated glucose and FFA on islet
glucose sensing appear to be additive (see Fig. 2),
and as such food restriction would not be expected
to reduce basal insulin release in ob/ob mice.
The cellular mechanism(s) by which islet basal in-
sulin release was reduced in treated ob/ob mice was
next investigated. There are several intracellular can-
didates that may a¡ect islet glucose sensing via en-
ergy metabolism or second messenger systems. In
normal pancreatic L-cells, there is little hexokinase
activity [32] and glucokinase determines the thresh-
old of glucose-stimulated insulin release [33]. How-
ever, the situation appears to be di¡erent in obese-
hyperinsulinemic states. Studies have found an in-
crease of islet hexokinase activity in obese or diabetic
conditions [34,35], as well as in a L-cell line cultured
in high FFA medium [10]. Elevated hexokinase ac-
tivity may increase glucose phosphorylation at low
glucose levels and thus induce an increased basal
insulin release. Here we also found that in ob/ob
controls, islet hexokinase activity was 2-fold higher
than that in lean mice. Moreover, after BC/SKF
treatment, the hexokinase activity was signi¢cantly
reduced by 40% and the ratio of glucokinase to hex-
okinase activity was increased approximately 2-fold.
The relative decrease of hexokinase activity corre-
lated well with the decrease of elevated basal insulin
release from islets of treated mice versus controls
further suggesting an increased hexokinase activity
in L-cells may contribute to the enhanced basal in-
sulin release in ob/ob mice. However, these data must
be interpreted with some caution, because the distri-
bution of hexokinase in K and N cells is much higher
than that in L cells. Assay of puri¢ed L-cells or islet
immunocytochemical analysis is necessary to de¢ne
the islet cell type within which the hexokinase activ-
ity is increased. The impact of increased hexokinase
activity on high basal insulin release requires and
deserves further evaluation. Increased glucose cycling
may diminish the impact of high hexokinase activity
on glycolysis and thereby on insulin release [36];
however, the evidence for this is rather questionable
[37].
It is well known that cAMP is an intracellular
mediator of glucose-stimulated insulin release. Cyclic
AMP also has regulatory e¡ects on hexokinase and
carnitine palmitoyltransferase I expression [38,39],
and both enzymes may in£uence islet energy metab-
olism and fuel-induced insulin release. We therefore
examined the cAMP content in pancreatic islets of
these mice. After BC/SKF treatment, the elevated
cAMP level of ob/ob controls dropped by 50%
(P6 0.05) to levels similar to that in lean mice. The
di¡erence of islet cAMP content between control and
treated ob/ob mice correlates with di¡erences in basal
insulin release from respective isolated islets suggest-
ing that a deceased cAMP content in islets may be
partially responsible for the reduction of the elevated
basal insulin release in treated ob/ob mice. In ob/ob
mice, the high plasma glucagon level may stimulate
cAMP production in L-cells and thus contribute to
hyperinsulinemia in these mice [40,41]. In our present
study, the plasma glucagon level in the ob/ob mice
was 3-fold higher than that in lean mice. BC/SKF
treatment signi¢cantly reduced the plasma glucagon
to levels observed in lean mice. This may, in part,
explain the reduction of islet cAMP in BC/SKF-
treated mice.
PKC isoforms are second messengers which par-
ticipate in the process of stimuli-secretion coupling in
pancreatic islets. In islets from ob/ob mice, the sensi-
tivity to PKC stimulation is enhanced [23,42]. Hyper-
glycemia and hyperlipidemia may increase islet long
chain acyl-CoA content, which is a potent regulator
of some PKC isoforms [12]. Therefore, we speculated
that an increased PKC level in islets might also be
responsible for the high basal insulin release in ob/ob
mice. Although we found di¡erences of PKC-K and
PKC-O levels between the lean and ob/ob mice, BC/
SKF treatment did not change the content or the
distribution of these two PKC isoforms. The disso-
ciation between the reduction of basal insulin release
and no change in PKC-immunoreactive levels in is-
lets from BC/SKF-treated mice seems not to favor an
important role for PKC-K or PKC-O in the BC/SKF
regulation of basal insulin release. It should be real-
ized that other PKC isoforms (e.g., PKC-N, PKC-j
or PKC-L) are also involved in insulin release [43].
More work is required to ascertain whether these
other PKC isoforms mechanistically participate in
altered islet glucose sensing and the BC/SKF e¡ect
therein.
In islets from BC/SKF-treated mice, we observed
BBAMCR 14364 9-10-98
Y. Liang et al. / Biochimica et Biophysica Acta 1405 (1998) 1^1310
an increased insulin release at high glucose levels
when insulin release was expressed per DNA content
in islet. This increased islet response to high glucose
(s 10 mM) in vitro does not necessarily con£ict with
the reduced plasma insulin level in these BC/SKF-
treated mice (see Table 1), since the plasma insulin
level is regulated by multiple factors beyond nutri-
tional components, including the autonomic nervous
system and hormones which are impacted by BC/
SKF treatment. For example, BC and/or BC/SKF
administration reduce hepatic glucose output and
lipolysis [44^46,52]; however, they also dramatically
decrease plasma glucagon (this study) and hypo-
thalamic NPY and norepinephrine content [47^49],
and such activities are known to reduce plasma in-
sulin level [50]. If insulin release was calculated as
the fraction of islet insulin content, BC/SKF-treated
mice showed a lower release fraction than that in
controls, suggesting that increased insulin storage
in BC/SKF-treated mice may explain the higher islet
insulin response to high glucose [13]. The increased
islet insulin content in BC/SKF-treated mice could
be a result of a reduction of insulin release in vivo
manifested as a decreased plasma insulin level. This
assumption is supported by a recent report that
chronic exposure to hyperlipidemia decreased islet
insulin content as the result of increased basal insu-
lin release although there was an increase in the
proinsulin biosynthesis [51]. Further studies on insu-
lin biosynthesis in ob/ob mice treated with BC/SKF
will provide more needed information on this issue.
In summary, daily treatment of ob/ob mice with
BC/SKF for 2 weeks reduced hyperglycemia, hyper-
lipidemia, and the elevated basal insulin release from
freshly isolated islets. Our data suggest that BC/
SKF-induced improvement of islet function may be
mediated in part by its e¡ect to reduce hyperglycemia
and hyperlipidemia. This reduced basal insulin re-
lease appears to involve a reduction of islet hexoki-
nase activity as well as of cAMP content and/or ac-
tion.
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